Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: J Affect Disord. 2016 Oct 26;208:560–566. doi: 10.1016/j.jad.2016.10.026

Table 1.

Demographic and Clinical Data of Subjects Receiving Ketamine, Separated by Antidepressant Response at Two Weeks

Responders at Two
Weeks (n=12)
mean (SD)
Non-Responders at
Two Weeks
(n=81)
mean (SD)
Age, years 43.8 (12.4) 43.7 (12.8)
Body mass index 32.7 (9.0) 28.9 (6.3)
Age of Onset, years 23.9 (11.9) 17.6 (8.8)
Length of Illness, years 19.9 (10.0) 26.0 (12.7)
Length of Current Depressive Episode,
 months
65.8 (111.4) 50.5 (93.6)
Number of Previous Episodes 29.5 (44.0) 30.5 (40.4)
Total Lifetime Medication Trials 5.7 (3.0) 8.0 (4.3)
Clinical Ratings (at baseline)
 MADRS 31.6 (3.1) 33.0 (5.0)
 BDI 25.8 (6.9) 28.1 (8.7)
 HAM-A 19.7 (3.4) 21.2 (5.2)
Percent change in MADRS score
 230 min −60.4 (28.6) −31.4 (34.7)
 1 day −62.5 (30.9) −28.6 (34.5)
 14 days −66.1 (14.8) −10.0 (19.8)
n (%) n (%)
Education
 Not College Grad 7 (58.3) 33 (42.3)
 College Grad 5 (41.7) 45 (57.7)
Sex, female 5 (41.7) 44 (54.3)
Race/ethnicity, white 11 (91.7) 72 (91.1)
Diagnosis (bipolar disorder) 2 (20.0) 21 (36.8)
Lifetime History of
 Suicide Attempt 6 (50.0) 30 (38.5)
 Anxiety Disorder 5 (50.0) 30 (54.5)
 Alcohol Abuse 2 (16.7) 20 (28.6)
 Substance Abuse (non-nicotine) 6 (50.0) 27 (36.5)
 Abuse
  Physical 4 (40.0) 14 (23.0)
  Sexual 4 (40.0) 13 (21.3)
Family History Alcohol Use Disorder, 1st
 Degree Relative
6 (50.0) 28 (35.4)

Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; BDI, Beck Depression Inventory; HAM-A, Hamilton Anxiety Rating Scale